Biotech | March 01, 2022
Novavax UK Phase 3 trial demonstrates protection from Covid-19 over six-month period
High level of vaccine efficacy maintained over a 6-month period of surveillance
High level of vaccine efficacy maintained over a 6-month period of surveillance
This collaboration aims at capturing translational disease insights from large external healthcare biobanks and maximizing value of data for drug discovery and precision medicine
Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m
The NMPA Breakthrough Therapy Designation was based on results from the Phase 2 TRUST trial of ROS1 fusion-positive NSCLC patients treated with taletrectinib, a new generation of potent ROS1 inhibitors
This innovative biomanufacturing technology will help to deliver cost-effective viral production that is unmatched in the industry
Company has bought 7.73 million shares for KRW 146.1 billion thus securing the largest shareholder status in Bukwang Pharmaceutical
Thermo Fisher and Symphogen extend their collaboration using innovative and efficient workflows to improve data confidence, aiding the creation of new cancer treatments
BBL will gain Viatris’ global biosimilars business whose revenues are estimated to be USD 1 billion next year, along with its portfolio of in-licensed biosimilar assets
It is the first approved blood test that can predict likely progression to Alzheimer's Disease up to six years in advance
This medicine was previously available in 40mg and 80mg strength, for which patients had to consume 2 tablets a day as per the approved dosage
Subscribe To Our Newsletter & Stay Updated
